-
公开(公告)号：US20070014760A1
公开(公告)日：2007-01-18
申请号：US11183355
申请日：2005-07-18
申请人： Gholam Peyman
发明人： Gholam Peyman
IPC分类号： A61K38/19 , A61K38/18 , A61K38/13 , A61K31/7048 , A61K31/4745 , A61K31/56 , A61K31/60 , A61K31/192
CPC分类号： A61K31/192 , A61K31/365 , A61K31/436 , A61K31/56 , A61K31/60 , A61K31/7048 , A61K38/13 , A61K38/185 , A61K38/204 , A61K38/2093 , A61K2300/00
摘要： An ocular method comprising localized ocular administration of a pharmaceutically acceptable formulation and effective concentration of at least one neuro-stimulatory agent, which may include a macrolide, for a duration sufficient to at least partially restore corneal sensation, or at least one macrolide to reduce scarring after ocular surgery. The neuro-stimulatory agent may be one or more of a macrolide, macrolide analog, neurotrophin, or neuropoietic factor. The method is used in a patent following ocular surgery, such as vision-correction surgery, glaucoma surgery, or retinal detachment repair surgery.
摘要翻译： 一种眼睛方法，其包括局部眼睛施用药学上可接受的制剂和有效浓度的至少一种神经刺激剂，其可以包括大环内酯，持续时间足以至少部分地恢复角膜感觉，或至少一种大环内酯以减少瘢痕形成 眼手术后。 神经刺激剂可以是大环内酯类，大环内酯类似物，神经营养蛋白或神经生成因子中的一种或多种。 该方法用于眼外科手术后的专利，例如视力矫正手术，青光眼手术或视网膜脱离修复手术。
-
公开(公告)号：US20060259138A1
公开(公告)日：2006-11-16
申请号：US11431176
申请日：2006-05-09
申请人： Gholam Peyman
发明人： Gholam Peyman
IPC分类号： A61F2/16
CPC分类号： A61F2/1613 , A61F2/1602 , A61F2/1648 , A61F2/1651 , A61F2250/0053
摘要： The present invention relates to an intraocular lens. The intraocular lens includes a lens having an opening therein and an ocular system capable of being inserted into the opening after implantation into an eye. Wherein the first lens is adapted to project a first image onto the retina and the second lens is adapted to project a second image onto the retina.
摘要翻译： 眼内透镜本发明涉及眼内透镜。 眼内透镜包括其中具有开口的透镜和在植入眼睛之后能够插入开口中的眼睛系统。 其中第一透镜适于将第一图像投影到视网膜上，并且第二透镜适于将第二图像投影到视网膜上。
-
公开(公告)号：US20060251712A1
公开(公告)日：2006-11-09
申请号：US11485352
申请日：2006-07-13
申请人： Gholam Peyman
发明人： Gholam Peyman
IPC分类号： A61K38/14 , A61K31/704 , A61N1/39 , A61K9/127 , A61K33/24 , A61K31/407
CPC分类号： A61K41/0052
摘要： A method for the hyperthermia treatment of tissue in a target site applies a heat source to kill cells without protein denaturization. The method introduces an encapsulated dye that is released at a selected temperature in the target site to indicate that a threshold temperature has been reached to hyperthermally treat the tissue. In one embodiment, the composition releases the dye at a temperature of 42° C. to 50° C., and preferably about 45° C. to 49° C. The composition which can be a liposome composition encapsulating the dye can be introduced to the bloodstream of the patient to flow through the target site.
-
公开(公告)号：US07037943B2
公开(公告)日：2006-05-02
申请号：US09832269
申请日：2001-04-10
申请人： Gholam Peyman
发明人： Gholam Peyman
IPC分类号： A61K31/135
CPC分类号： A61N1/36046 , A61F9/0017 , A61K9/0051 , A61N2005/0652 , Y10S514/912
摘要： A method for treating or preventing retinal pathology or injury. The method locates and secures a retinal stimulating substance in the eye between the internal limiting membrane and the retina, which is the target site for the substance. The substance may be an implant that provides electrical stimulation to adjacent ganglion and neurofiber cells. Alternatively, the substance may be a pharmaceutical substance to stimulate the retina. In addition to providing direct contact of the substance with its target, the method obviates the need for artificial structures such as tacks or adhesives which may cause retinal bleeding or traction.
-
公开(公告)号：US20050283109A1
公开(公告)日：2005-12-22
申请号：US11180214
申请日：2005-07-13
申请人： Gholam Peyman
发明人： Gholam Peyman
CPC分类号： A61F9/00772 , A61F2210/0004 , A61L31/148
摘要： A plug is presented. The plug includes biodendrimer and is suitably sized and shaped to be placed within a punctum or a lacrimal canal of an eye. The plug, when placed within the punctum or the lacrimal canal for approximately six months, can at least partly occlude the punctum or the lacrimal canal throughout the approximately six months. The plug can completely dissolve or partially dissolve and fall out of the punctum or the lacrimal canal after the approximately six months. A method of treating an eye is also presented. The method includes introducing biodendrimer into a punctum or a lacrimal canal of the eye and polymerizing the biodendrimer such that the polymerized biodendrimer at least partly occludes the punctum or the lacrimal canal for at least approximately six months.
摘要翻译： 提供一个插头。 塞子包括生物聚合物，并且适当地尺寸和形状被放置在眼睛的泪点或泪管内。 塞子当放置在泪点或泪道内大约六个月时，可以在大约六个月内至少部分地阻塞泪点或泪道。 约六个月后，塞子可以完全溶解或部分溶解并从泪点或泪道中脱落。 还提出了一种治疗眼睛的方法。 该方法包括将生物聚合物引入眼睛的泪点或泪道并聚合生物聚合物，使得聚合的生物聚合物至少部分地将泪点或泪道阻塞至少约六个月。
-
公开(公告)号：US20050234531A1
公开(公告)日：2005-10-20
申请号：US11154229
申请日：2005-06-16
申请人： Gholam Peyman
发明人： Gholam Peyman
CPC分类号： A61F9/008 , A61F9/00821 , A61F2009/00863 , A61N5/062
摘要： Age-related macular degeneration (AMD) results in the formation of new blood vessels in the eye. The walls of these vessels leak fluid, which causes scarring in the surrounding tissue and results in reduced vision or loss of vision. Photodynamic therapy (PDT) alone has been used to treat AMD, but many retreatments are needed, which cause further damage to the already diseased area. Laser treatment to coagulate the fluid actually causes additional new vessels to form. However, the inventive method of treating patients with both PDT and scatter threshold laser coagulation therapy surprisingly either improved vision, or prevented further loss of vision. Moreover, the combined treatment eliminated the need for retreatment, and did not generate new vessel growth. Threshold laser coagulation and PDT may be administered within the same treatment session or either may be administered first and the other may be administered within ninety days.
-
公开(公告)号：US20050149006A1
公开(公告)日：2005-07-07
申请号：US11070659
申请日：2005-03-02
申请人： Gholam Peyman
发明人： Gholam Peyman
CPC分类号： A61F9/008 , A61B18/04 , A61B18/18 , A61F9/00827 , A61F9/00834 , A61F9/009 , A61F2007/0004 , A61F2007/0054 , A61F2009/00853 , A61F2009/00872 , A61F2009/0088
摘要： A system and method for correcting the refractive error in the cornea of an eye. A short pulse laser is aimed at a predetermine depth in the cornea, below the exterior surface of the cornea. The short pulse laser is then fired, such that the short pulse laser ablates at least two three dimensional portions below the exterior surface of the cornea, thereby softening the cornea. The cornea is heated and reshaped, so that the cornea substantially conforms to a predetermined shape.
摘要翻译： 用于校正眼睛角膜屈光不正的系统和方法。 短脉冲激光瞄准角膜的预定深度，在角膜的外表面下方。 短脉冲激光然后被烧制，使得短脉冲激光在角膜的外表面下方消融至少两个三维部分，从而软化角膜。 角膜被加热并重新成形，使得角膜基本上符合预定的形状。
-
公开(公告)号：US20240293224A1
公开(公告)日：2024-09-05
申请号：US18662925
申请日：2024-05-13
申请人： Gholam Peyman
CPC分类号： A61F2/1648 , A61L27/16 , A61L27/50 , A61F2002/0081 , A61F2002/1689 , A61F2002/16965 , A61F2240/001 , A61F2250/0091 , A61L2400/12 , A61L2430/16 , B33Y40/20 , B33Y80/00
摘要： An apparatus has a central lens body for providing vision correction for a patient. The lens body has a central aperture and is configured as one of: a diffractive lens or a refractive lens. The lens body has at least one haptic extending from the lens body, and the central aperture has a form of a circular hole extending fully through the lens body when the apparatus is implanted in the eye. The lens body is formed from a substantially transparent material and the central aperture includes a darkened perimeter. The darkened perimeter of the central aperture includes a darkened internal wall extending through the lens body from an anterior surface to a posterior surface of the lens body.
-
公开(公告)号：US10660743B2
公开(公告)日：2020-05-26
申请号：US16140801
申请日：2018-09-25
摘要： An intraocular lens has central lens body at least one haptic extending from the central lens body. The haptic has a lobular configuration. The lens body and the haptic having a folded configuration for implantation within the eye. The lens having a first deployed configuration wherein the lens body is positioned at a location substantially behind sealed anterior and posterior portions of the lens capsule with the at least one haptic positioned at a location substantially over top of the sealed anterior and posterior portions of the lens capsule. The lens having a second deployed configuration wherein the lens body is positioned at a location substantially in front of the sealed anterior and posterior portions of the lens capsule with the at least one haptic positioned at a location substantially over behind the sealed anterior and posterior portions of the lens capsule.
-
公开(公告)号：US20200093588A1
公开(公告)日：2020-03-26
申请号：US16140801
申请日：2018-09-25
摘要： An intraocular lens has central lens body at least one haptic extending from the central lens body. The haptic has a lobular configuration. The lens body and the haptic having a folded configuration for implantation within the eye. The lens having a first deployed configuration wherein the lens body is positioned at a location substantially behind sealed anterior and posterior portions of the lens capsule with the at least one haptic positioned at a location substantially over top of the sealed anterior and posterior portions of the lens capsule. The lens having a second deployed configuration wherein the lens body is positioned at a location substantially in front of the sealed anterior and posterior portions of the lens capsule with the at least one haptic positioned at a location substantially over behind the sealed anterior and posterior portions of the lens capsule.
-
-
-
-
-
-
-
-
-
搜索结果
92 条记录 (耗时 0.024 秒)
